5395242025-07-012025-09-305395242025-09-305395242025-03-315395242025-04-012025-09-305395242025-07-012025-09-30in-capmkt:OtherExpenses1Member5395242025-07-012025-09-30in-capmkt:OtherExpenses2Member5395242025-04-012025-09-30in-capmkt:OtherExpenses1Member5395242025-04-012025-09-30in-capmkt:OtherExpenses2Member5395242025-07-012025-09-30ItemsThatWillNotBeReclassifiedToProfitAndLoss15395242025-04-012025-09-30ItemsThatWillNotBeReclassifiedToProfitAndLoss15395242025-07-012025-09-30ItemsThatWillBeReclassifiedToProfitAndLoss15395242025-04-012025-09-30ItemsThatWillBeReclassifiedToProfitAndLoss1iso4217:INRiso4217:INRxbrli:shares539524LALPATHLABNOTLISTEDINE600L01024Dr. Lal Path Labs Ltd.Main BoardEquity2025-04-012026-03-312025-10-312025-10-24INRMillionsQuarterlySecond quarterSingle segmentThe business of running laboratories for carrying out Pathological investigations of various branches of Bio-chemistry, Hematology, Histopathology, Microbiology, Electrophoresis, Immuno-chemistry, Immunology, Virology, Cytology, other pathological and radiological investigations.2025-10-3110:30:002025-10-3113:55:00trueCash Flow IndirectNot applicable2025-07-012025-09-30UnauditedConsolidated73060000002480000007554000000141800000000132200000048000000405000000232500000055180000002036000000020360000004730000004100000051400000001522000000000015220000001500000015370000001506000000160000001521000000160000008380000001018.0518.010018.0518.01i. The above consolidated results were reviewed by the Audit Committee and approved by the Board of Directors in their respective meetings held on 31 October, 2025. The limited review, as required under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, has been completed by the Statutory Auditors for the quarter and six months ended September 30, 2025 and they have expressed an unmodified conclusion on the aforesaid results. <BR> ii. The above consolidated results represent consolidated results of the Company and its subsidiaries (together referred to as 'the Group'). <BR> iii. These financial results of the Group have been prepared in accordance with the recognition and measurement principles laid down in the Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. <BR> iv. During the six months ended 30 September 2025, the Parent Company has issued 183,775 equity shares of face value of INR 10 each , to "Dr. Lal Pathlabs Employee Welfare Trust" under Employee Stock Option Plan, 2022 ("ESOP Plan, 2022"). <BR> v. The Board of Directors of the Parent Company have approved second interim dividend of INR 7 per equity share (face value of INR 10 each) at their meeting held on 31 October, 2025. <BR> The Board of Directors of the Parent Company had approved an interim dividend of INR 6 per equity share (face value of INR 10 each) at their meeting held on 31 July, 2025 which was paid on 14 August, 2025 <BR> The Board of Directors of the Parent Company had proposed final dividend of INR 6 per equity share (face value of INR 10 each) for the financial year ended 31 March, 2025. The same was approved by the shareholders in the Annual General Meeting held on 28 June, 2025 and this was paid on 2 July, 2025. <BR> vi. The Hon’ble Allahabad Bench of the National Company Law Tribunal (‘Hon’ble Tribunal’ or ‘NCLT’) sanctioned the Scheme of Amalgamation ('Scheme') between the subsidiaries Paliwal Medicare Private Limited (PMPL) (Transferor Company) and Paliwal Diagnostics Private Limited (PDPL) (Transferee Company) on 3 September, 2024. The appointed date as per Scheme was 1 April, 2021. The Scheme had envisaged transfer of all properties, rights, assets, interests and claims of the Transferor Company to the Transferee Company.Pursuant to the Scheme becoming effective, the amalgamation had been accounted for under the ‘pooling of interests’ method in accordance with Ind AS 103 “Business Combinations” and the assets, liabilities and reserves of the Transferor Company had been accounted for at their book value, in the books of Transferee Company. <BR> vii. The Board of the Parent Company had earlier noted approval by the board of Suburban Diagnostics India Private Limited ("SDIPL"), a wholly owned subsidiary of the Company for voluntary liquidation of SDIPL under the provisions of Insolvency and Bankruptcy Code, 2016, wherein the business undertaking of SDIPL was sought to be distributed to the Company on a going concern basis. The shareholders of SDIPL at their Extra-Ordinary General Meeting held on 6 February, 2025 also accorded approval for the voluntary liquidation of SDIPL. On 18 March, 2025, the liquidator of SDIPL based on the approved scheme has distributed the entire business undertaking of SDIPL to the Company, on a going concern basis. <BR> The above distribution resulted in inter-alia recognition of long term service agreements in block of intangible assets in tax books of the Company at fair value on 18 March, 2025. Accordingly, deferred tax credit of INR 408 million has been recognised in statement of profit or loss for the quarter and year ended 31 March 2025. <BR> viii. The Board of Director's of Parent company at their meeting held on 31 October, 2025 approved issuance of bonus shares, in the proportion of 1:1 i.e 1 (one) bonus equity share of INR 10 each for every 1 (one) fully paid-up equity share , subject to Shareholders approvals. <BR> ix. During the year ended 31 March 2025, Dr. Lal PathLabs Kenya Private Limited (Wholly Owned Subsidiary), a Company incorporated in the Republic of Kenya, was dissolved and its name was struck off, with effect from the date of publication of gazette notification dated 13 September, 2024. <BR> x. As at 30 September,2025, the Parent company has the following subsidiaries: <BR> Subsidiaries <BR> Paliwal Diagnostics Private Limited <BR> Dr. Lal PathLabs Nepal Private Limited <BR> Dr. Lal PathLabs Bangladesh Private Limited <BR> Dr. Lal Ventures Private Limited <BR> PathLabs Unifiers Private Limited <BR> Step-down subsidiaries <BR> Centrapath Labs Private Limited <BR> APRL PathLabs Private Limited <BR> Chanre Laboratory Private Limited <BR> <BR> JV/Associate Company- Nil <BR> <BR> xi. The Board of Directors, which has been identified as being the chief operating decision maker (CODM), evaluates the Group's performance, allocates resources based on the analysis of the various performance indicators of the Group as a single unit. Therefore there is no reportable segment for the Group, in accordance with the requirements of Indian Accounting Standard 108 - 'Operating Segments', notified under the Companies (Indian Accounting Standard) Rules, 2015. <BR> xii. Refer to Annexure - A for Statement of Consolidated Assets and Liabilities and Annexure-B for Consolidated Cash Flow Statement. <BR> 2025-04-012025-09-30UnauditedConsolidated1400400000052900000014533000000270700000000264500000095000000751000000448800000010686000000384700000003847000000923000000620000009850000000286200000000002862000000600000028680000002830000000320000002836000000320000008380000001033.9333.870033.9333.87Fees to collection centers/channel partners1063000000Other expenses1262000000Fees to collection centers/channel partners1985000000Other expenses25030000004293000000166000000332000000548100000022090000001000000000000834000000834000000798000000273000000143960000005020000004855000000101100000011610000007001000000180000003800000001442600000002680000001519600000000295920000008380000002304000000023878000000343000000242210000000000989000000989000000210000002900000000103900000002120000001701000000191300000012150000003128000000503000000411000000290000000043320000000053710000002959200000095000000-141000000-1500000000-4600000000-2600000001190000000-12100000007510000000610000000280000000003350000001380000000000-1490000000224000000407100000000083100000003240000000000000004000000134400000000048000000000000000000004720000000-2964000000-3880000000000000177000000000180000000102700000010000000-94000000-1125000000-17650000000-176500000029260000001161000000Remeasurement of the defined benefit obligations1800000018000000Remeasurement of the defined benefit obligations6000000600000050000002000000Exchange differences on translation of foreign operations20000002000000Exchange differences on translation of foreign operations2000000200000000150000006000000